Table 2

Baseline IGF geometric means (nmol/l, and 95% CI) in women ≤50 and >50 years of age allocated to fenretinide or no treatment (control)

Age ≤50 yearsAge >50 years
Fenretinide (n = 30)Control (n = 29)Fenretinide (n = 30)Control (n = 29)
IGF-I24.1 (20.4–28.6)25.6 (22.0–30.0)14.6 (12.3–17.4)13.8 (11.5–16.6)
IGFBP-3101.9 (90.5–114.7)102.1 (92.2–113.1)73.7 (69.2–78.6)79.0 (72.1–86.5)
IGF-I:IGFBP-30.2 (0.2–0.3)0.3 (0.2–0.3)0.2 (0.2–0.2)0.2 (0.2–0.2)
IGF-II65.1 (57.1–74.2)69.2 (62.4–76.8)
IGFBP-10.9 (0.7–1.2)1.1 (0.9–1.5)
IGFBP-29.1 (7.5–11.0)9.7 (8.1–11.7)
Free IGFsa0.8 (0.7–0.9)0.9 (0.8–0.9)
  • a (IGF-I + IGF-II):(IGFBP-1 + IGFBP-2 + IGFBP-3) molar ratio.